Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
暂无分享，去创建一个
G. Haas | N. Agarwal | A. Armstrong | C. Higano | D. Penson | C. Olsson | J. Sugg | William T. Duggan | L. Karsh | R. Concepcion | C. Dunshee | Q. Shen | W. Duggan
[1] T. Tammela,et al. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. , 2020, The New England journal of medicine.
[2] F. Saad,et al. Apalutamide and Overall Survival in Prostate Cancer. , 2020, European urology.
[3] F. Saad,et al. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.
[4] M. Botteman,et al. Treatment characteristics for nonmetastatic castration-resistant prostate cancer in the United States, Europe and Japan. , 2019, Future oncology.
[5] F. Saad,et al. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. , 2019 .
[6] M. Stockler,et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.
[7] T. Tammela,et al. Darolutamide in Nonmetastatic, Castration‐Resistant Prostate Cancer , 2019, The New England journal of medicine.
[8] F. Saad,et al. Enzalutamide in Men with Nonmetastatic, Castration‐Resistant Prostate Cancer , 2018, The New England journal of medicine.
[9] F. Saad,et al. Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer , 2018, The New England journal of medicine.
[10] N. Agarwal,et al. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.